Skip to content

Study · Animal study (in vivo) · rat · 2013

3 results

Antidiuretic effect of desmopressin chimera agglomerates by nasal administration in rats.

Balducci AG, Ferraro L, Bortolotti F, Nastruzzi C, Colombo P, Sonvico F, Russo P, Colombo G

International journal of pharmaceutics6 Oct 2012Cited by 22 (Europe PMC)

PMID23046665 (opens in a new tab)DOI10.1016/j.ijpharm.2012.09.049 (opens in a new tab)PepBankPUB-23046665
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, desmopressin agglomerates significantly reduced urine production.

    In plain wordsIn rats, desmopressin agglomerates reduced urine production.

    Peptide
    Desmopressin
    Outcome
    DecreaseUrine production
    Study

    ratn: not reported in source

    nasal desmopressin administration
    Outcome group
    Urine Production · Kidney and urinary
    Studied dose
    Dose not stated · intranasalAs given in this study (rat).

    Source sentences

    Summary
    The administration of DDAVP agglomerates induced a significant reduction in urine production.
    1 context sentence
    Summary · context
    In the present study, a nasal powder of the antidiuretic peptide desmopressin (DDAVP) formulated as chimera agglomerates was studied to improve drug bioavailability and provide a flexible drug product.

Studies that did not test the peptide alone2

In this study, Desmopressin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Desmopressin.

  1. 02AnimalNot a test of Desmopressin aloneAnimal study (in vivo)Other

    In rats, the device delivered almost 80% of loaded desmopressin agglomerate powder into the nose.

    In plain wordsIn rats, almost 80% of loaded desmopressin powder entered the nose.

    Peptide
    Desmopressin
    Outcome
    Not applicablePowder delivery
    Study

    ratn: not reported in source

    nasal desmopressin administration
    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    In rats, intranasal DDAVP agglomerates allowed for efficient administration with almost 80% of the loaded powder emitted from the device into the animal nose.
    1 context sentence
    Summary · context
    In the present study, a nasal powder of the antidiuretic peptide desmopressin (DDAVP) formulated as chimera agglomerates was studied to improve drug bioavailability and provide a flexible drug product.

    In this study, Desmopressin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Desmopressin.

  2. 03AnimalNot a test of Desmopressin aloneAnimal study (in vivo)Efficacy outcome

    In rats, nasal desmopressin agglomerates had no significantly different antidiuretic effect from intravenous desmopressin at a ten-fold lower dose.

    In plain wordsIn rats, nasal desmopressin's antidiuretic effect did not significantly differ from intravenous desmopressin at a ten-fold lower dose.

    Peptide
    Desmopressin
    Outcome
    No significant changeAntidiuretic effect
    Study

    ratn: not reported in source

    nasal desmopressin administration
    Comparator
    Intravenous desmopressin at a ten-fold lower dose
    Outcome group
    Urine Production · Kidney and urinary

    Source sentences

    Summary
    Moreover, the antidiuretic effect of agglomerates did not significantly differ from the one induced by an intravenous injection of DDAVP at a ten-fold lower dose.
    2 context sentences
    Summary · context
    In rats, intranasal DDAVP agglomerates allowed for efficient administration with almost 80% of the loaded powder emitted from the device into the animal nose.
    Summary · context
    In the present study, a nasal powder of the antidiuretic peptide desmopressin (DDAVP) formulated as chimera agglomerates was studied to improve drug bioavailability and provide a flexible drug product.

    In this study, Desmopressin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Desmopressin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.